{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:28Z","timestamp":1791912508588,"version":"4.3.4"},"reference-count":38,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14712598.2023.2296126","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:54:13Z","timestamp":1702630453000},"page":"1163-1171","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-9751","authenticated-orcid":false,"given":"Alexandria","family":"Matic","sequence":"first","affiliation":[{"name":"The Ellen &amp; Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf","family":"Alfaidi","sequence":"additional","affiliation":[{"name":"The Ellen &amp; Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"The Ellen &amp; Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_3_5_4_1","unstructured":"Howard JF Clinical overview of MG. Myasthenia gravis Foundation of America. [cited 2023 Aug 30]. Available from: https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201501"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2082946"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0901"},{"key":"e_1_3_5_15_1","unstructured":"UCB announces approval of RYSTIGGO[\u00ae] (rozanolixizumab) and ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan. Brussels Belgium: UCB New Press Release; [cited 2023 Sep 25-28]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S377056"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_5_18_1","unstructured":"FDA approves New treatment for myasthenia gravis. FDA News Release. 2021 Dec 17 [cited 2023 Jul 20]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.363824"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad208"},{"key":"e_1_3_5_22_1","unstructured":"Highlights of prescribing information: Rozanolixizumab-noli. US Food & Drug Administration Access data. 2023 [cited 2023 Sep 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"#cr-split#-e_1_3_5_25_1.1","unstructured":"A randomized open-label extension study to investigate the long-term safety tolerability and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis ClinicalTrials.Gov identifier: NCT04124965. [Updated 2023 Sep 5"},{"key":"#cr-split#-e_1_3_5_25_1.2","unstructured":"cited 2023 Sep 5-15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04124965"},{"key":"#cr-split#-e_1_3_5_26_1.1","unstructured":"An open-Label extension study to evaluate rozanolixizumab in study participants with generalized myasthenia gravis. ClinicalTrials.gov identifier: NCT04650854. [Updated 2023 Sep 15"},{"key":"#cr-split#-e_1_3_5_26_1.2","unstructured":"cited 2023 Sep 15-21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04650854"},{"key":"#cr-split#-e_1_3_5_27_1.1","unstructured":"An Open-Label crossover study to evaluate rozanolixizumab self-administration by study participants with generalized myasthenia gravis. ClinicalTrials.Gov identifier: NCT05681715. [Updated 2023 Sep 25"},{"key":"#cr-split#-e_1_3_5_27_1.2","unstructured":"cited 2023 Sep 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05681715"},{"issue":"3","key":"e_1_3_5_28_1","first-page":"S4","article-title":"Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy: randomized subject-\/Investigator-blind placebo-controlled Phase 2a trial. In: peripheral nerve society annual meeting 2022 abstract supplement","volume":"27","author":"Querol L","year":"2022","unstructured":"Querol L, de Seze J, Dysgaard T, et al. Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy: randomized subject-\/Investigator-blind placebo-controlled Phase 2a trial. In: peripheral nerve society annual meeting 2022 abstract supplement. J Peripheral Nerv Syst. 2022 Jul;27(S3):S4\u2013S183. Abstract: 66b","journal-title":"J Peripheral Nerv Syst"},{"key":"#cr-split#-e_1_3_5_29_1.1","unstructured":"A study to evaluate the efficacy safety and tolerability of rozanolixizumab in adult study participants with PersistRent or Chronic Primary immune Thrombocytopenia (ITP) (myOpportunity1). ClinicalTrials.Gov Identifier: NCT04200456. [Updated 2023 Aug 08"},{"key":"#cr-split#-e_1_3_5_29_1.2","unstructured":"cited 2023 Sep 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04200456"},{"key":"#cr-split#-e_1_3_5_30_1.1","unstructured":"A randomized double-blind placebo-controlled multicenter Phase 3 pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with Myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD). ClinicalTrials.Gov Identifier: NCT05063162. [Updated 2023 Aug 21"},{"key":"#cr-split#-e_1_3_5_30_1.2","unstructured":"cited 2023 Sep 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05063162"},{"key":"e_1_3_5_31_1","first-page":"2","volume-title":"2022 AAN Summer Conference","author":"Dubey D","unstructured":"Dubey D, Titulaer MJ, Koul AD, et al. The first randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of an FcRn inhibitor, rozanolixizumab, in patients with leucine-rich glioma inactivated 1 autoimmune encephalitis. In: 2022 AAN Summer Conference; San Francisco and Virtual. 2022 Jul 16. Abstract. p. 2\u2013009."},{"key":"#cr-split#-e_1_3_5_32_1.1","unstructured":"A randomized double-blind placebo-controlled multicenter Phase 2A proof-of-concept study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. ClinicalTrials.Gov Identifier: NCT05643794. [Updated 2023 Sep 22"},{"key":"#cr-split#-e_1_3_5_32_1.2","unstructured":"cited 2023 Sep 22-25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05643794"},{"key":"e_1_3_5_33_1","unstructured":"UCB announces U.S. FDA approval of RYSTIGGO[\u00ae] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. Brussels Belgium: UCB News Press Release; 2023 June 27 [cited 2023 July 20]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis"},{"key":"e_1_3_5_34_1","unstructured":"UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority review. Brussels Belgium: UCB News press release; 2023 Jan 6 [cited 2023 Sep 16]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-rozanolixizumab-BLA-for-the-treatment-of-generalized-myasthenia-gravis-filed-with-US-FDA-and-designated-for-Priority-Review#:~:text=Brussels%20(Belgium)%206%20Jan%202023 that%20the%20Agency%20has%20granted"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2296126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:32:08Z","timestamp":1727206328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2296126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14712598.2023.2296126"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2296126","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}